Elanco Animal Health Inc (ELAN)
Elanco Animal Health Inc (ELAN) from its SEC filings: 2025 revenue $4.7 billion (+6% vs the year before), net margin -5%, free cash flow $284.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $4.7 billion |
| Revenue growth | +6% |
| Net income | -$232.0 million |
| Net margin | -4.9% |
| Free cash flow | $284.0 million |
| Diluted EPS | $-0.47 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +10% |
| Cash | $530.0 million |
| Long-term debt | $4.4 billion |
| Share count, 1 year | +1% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.